Fulcrum Therapeutics, Inc. is a clinical stage biopharmaceutical company. The company is headquartered in Cambridge, Massachusetts and currently employs 89 full-time employees. The company went IPO on 2019-07-18. The firm is focused on improving the lives of patients with genetically defined rare diseases in areas of high unmet medical need. The Company’s clinical product candidate, losmapimod, is developed for the potential treatment of facioscapulohumeral muscular dystrophy (FSHD). Its other clinical product candidate is FTX-6058, which is developed for the treatment of certain hemoglobinopathies, including sickle cell disease (SCD). The firm has developed a product engine to identify and validate cellular drug targets that can modulate gene expression to treat known root causes of genetically defined diseases. The Company’s product engine integrates patient-derived tissue and disease-relevant cell models that it interrogates using its pharmacologically diverse and annotated small-molecule compound library and customized CRISPR and RNAi libraries.